A Prospective Multicenter Diagnostic Biomarker Study to Discriminate Borderline from Stage I Invasive Ovarian Cancer
Active, not recruitingOBSERVATIONAL
Enrollment
400
Participants
Timeline
Start Date
September 3, 2024
Primary Completion Date
September 3, 2029
Study Completion Date
September 3, 2029
Conditions
Stage I Ovarian CancerBorderline Ovarian Tumors
Trial Locations (1)
3000
UZ Leuven, Leuven
All Listed Sponsors
lead
KU Leuven
OTHER
NCT06709872 - A Prospective Multicenter Diagnostic Biomarker Study to Discriminate Borderline from Stage I Invasive Ovarian Cancer | Biotech Hunter | Biotech Hunter